<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04843436</url>
  </required_header>
  <id_info>
    <org_study_id>CDC-00031</org_study_id>
    <nct_id>NCT04843436</nct_id>
  </id_info>
  <brief_title>RASM Post Market Clinical Follow Up Study</brief_title>
  <acronym>RASM PMCF</acronym>
  <official_title>RASM Post Market Clinical Follow Up Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MMI Spa</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MMI Spa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Post Market Clinical Follow up Study aimed to collect clinical data on safety and efficacy of&#xD;
      Robotically Assisted System called Symani to perform microsurgery techniques such as&#xD;
      anastomosis, suturing and ligation for open surgery procedures on small anatomical structures&#xD;
      such as blood vessels, lymphatic ducts and nerves.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PMCF study aimed to monitor the safety, usability, performance and long-term efficacy of&#xD;
      RASM. Furthermore it will permit to detect potential emerging risks related to safety on the&#xD;
      basis of eventual clinical evidence, through the observation of patients who have undergone&#xD;
      microsurgical reconstructions using the RASM Surgical System in the usual setting of standard&#xD;
      surgical practice after the introduction of RASM to the market.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 13, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Device Procedural Success</measure>
    <time_frame>Procedure</time_frame>
    <description>ability to complete the surgical task with RASM as intended by the surgeon</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time for anastomosis execution</measure>
    <time_frame>Procedure</time_frame>
    <description>Time for each anastomosis execution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative anastomosis repetition</measure>
    <time_frame>Procedure</time_frame>
    <description>need to repeat intraoperative anastomosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative redo</measure>
    <time_frame>14 days</time_frame>
    <description>need to repeat anastomosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major and Minor Complications</measure>
    <time_frame>14 days</time_frame>
    <description>major or minor complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Replantation Failure (for replantation)</measure>
    <time_frame>14 days</time_frame>
    <description>failure of replantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Flap Failure (for free flaps)</measure>
    <time_frame>14 days</time_frame>
    <description>failure of free flaps</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Limb volume reduction (for lymphatic surgery)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Limb volume reduction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Warm ischemia time</measure>
    <time_frame>Procedure</time_frame>
    <description>Time for warm ischemia</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Open Surgery</condition>
  <condition>Blood Vessels, Lymphatic Ducts and Nerves</condition>
  <condition>Free Flaps</condition>
  <arm_group>
    <arm_group_label>Symani</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients treated with Symani for any indications expressed in Inclusion/Exclusion criteria</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RASM Symani</intervention_name>
    <description>Robotically Assisted Micro Surgery</description>
    <arm_group_label>Symani</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who need a reconstructive procedure and a microsurgical reconstruction is&#xD;
             deemed the best option by the plastic, orthopedic or other surgeon in response to a&#xD;
             post-oncological, post-traumatic or congenital tissue defect or to treat lymphedema.&#xD;
&#xD;
          -  Patients who have been selected by the Clinical Registry Manager at the Clinical&#xD;
             Center as appropriate candidates for treatment with RASM in accordance with the&#xD;
             Instruction For Use (IFU).&#xD;
&#xD;
          -  Subjects who fit the criteria to perform surgery requiring reconstructions using free&#xD;
             flaps, replantations or lymphatic reconstructions.&#xD;
&#xD;
          -  Subjects who agree to have the surgery and the anesthesia.&#xD;
&#xD;
          -  Subjects who voluntarily decide to participate in this registry with the surgery&#xD;
             performed with the aid of the RASM Surgical System and sign the Informed Consent Form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who have bleeding or coagulation disorders in the past or present.&#xD;
&#xD;
          -  Any criteria that preclude prolonged anesthesia.&#xD;
&#xD;
          -  History of anaphylaxis or severe complicated allergy symptoms.&#xD;
&#xD;
          -  Clinically significant cardiovascular, digestive, respiratory, endocrine, or central&#xD;
             nervous system disorders or previous mental disorders that may significantly affect&#xD;
             the data collection or the ability to comply with the protocol.&#xD;
&#xD;
          -  Evidence or history of autoimmune disease or compromised immune system.&#xD;
&#xD;
          -  Participation in another clinical trial within 4 weeks prior to participation in the&#xD;
             registry.&#xD;
&#xD;
          -  Subjects belonging to vulnerable populations or ineligible to participate for other&#xD;
             reasons by a Clinical Registry Manager at a Clinical Center.&#xD;
&#xD;
          -  Subjects with pacemaker&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco Innocenti, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliero-Universitaria Careggi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paolo Silvestri, MSc</last_name>
    <phone>+39 050 879692</phone>
    <email>paolo.silvestri@mmimicro.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Innocenti, Prof.</last_name>
      <phone>+39055794111</phone>
      <email>marco.innocenti@unifi.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 8, 2021</study_first_submitted>
  <study_first_submitted_qc>April 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2021</study_first_posted>
  <last_update_submitted>June 22, 2021</last_update_submitted>
  <last_update_submitted_qc>June 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>microsurgery</keyword>
  <keyword>RASM</keyword>
  <keyword>free flaps</keyword>
  <keyword>lymphatic ducts</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

